Weverling GJ - Search Results

1

A comparison of serum HIV-1 RNA levels as measured by two quantitative assays in zidovudine-treated, asymptomatic, HIV-infected individuals.

Weverling GJ, Lange JM, de Jong MD, de Weerd H, Goudsmit J, de Wolf F. Weverling GJ, et al. Antivir Ther. 1996 Dec;1(4):255-63. Antivir Ther. 1996. PMID: 11324828 Clinical Trial.

2

HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.

Boucher CA, Lange JM, Miedema FF, Weverling GJ, Koot M, Mulder JW, Goudsmit J, Kellam P, Larder BA, Tersmette M. Boucher CA, et al. Among authors: weverling gj. AIDS. 1992 Nov;6(11):1259-64. doi: 10.1097/00002030-199211000-00003. AIDS. 1992. PMID: 1282015

3

Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.

Jurriaans S, Weverling GJ, Goudsmit J, Boogaard J, Brok M, Van Strijp D, Lange J, Koot M, Van Gemen B. Jurriaans S, et al. Among authors: weverling gj. AIDS Res Hum Retroviruses. 1995 Apr;11(4):473-9. doi: 10.1089/aid.1995.11.473. AIDS Res Hum Retroviruses. 1995. PMID: 7632462 Clinical Trial.

4

Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.

Godfried MH, van der Poll T, Mulder JW, Weverling GJ, Endert E, Lange JM, Sauerwein HP. Godfried MH, et al. Among authors: weverling gj. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):531-9. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 8548332 Clinical Trial.

5

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.

Reijers MH, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, Ten Kate RW, Mulder JW, Frissen PH, van Leeuwen R, Reiss P, Schuitemaker H, de Wolf F, Lange JM. Reijers MH, et al. Among authors: weverling gj. Lancet. 1998 Jul 18;352(9123):185-90. doi: 10.1016/s0140-6736(98)06193-5. Lancet. 1998. PMID: 9683207 Clinical Trial.

6

Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.

Weverling GJ, Lange JM, Jurriaans S, Prins JM, Lukashov VV, Notermans DW, Roos M, Schuitemaker H, Hoetelmans RM, Danner SA, Goudsmit J, de Wolf F. Weverling GJ, et al. AIDS. 1998 Jul 30;12(11):F117-22. doi: 10.1097/00002030-199811000-00003. AIDS. 1998. PMID: 9708401

7

Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.

Foudraine NA, Jurriaans S, Weverling GJ, Burger DM, Hoetelmans RM, Roos MT, Maas J, Miedema F, Reiss P, Portegies P, de Wolf F, Lange JM. Foudraine NA, et al. Among authors: weverling gj. Antivir Ther. 2001 Mar;6(1):55-62. Antivir Ther. 2001. PMID: 11417762 Clinical Trial.

8

Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.

Reiss P, Casula M, de Ronde A, Weverling GJ, Goudsmit J, Lange JM. Reiss P, et al. Among authors: weverling gj. HIV Med. 2004 Jan;5(1):11-4. doi: 10.1111/j.1468-1293.2004.00178.x. HIV Med. 2004. PMID: 14731163 Free article.

9

CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.

Wit FW, van Rij RP, Weverling GJ, Lange JM, Schuitemaker H. Wit FW, et al. Among authors: weverling gj. J Infect Dis. 2002 Dec 15;186(12):1726-32. doi: 10.1086/345677. Epub 2002 Nov 22. J Infect Dis. 2002. PMID: 12447757

10

Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.

Bogaards JA, Weverling GJ, Geskus RB, Miedema F, Lange JM, Bossuyt PM, Goudsmit J. Bogaards JA, et al. Among authors: weverling gj. Antivir Ther. 2003 Feb;8(1):43-50. Antivir Ther. 2003. PMID: 12713063

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123 results

Search Page

Filters